Apheresis
Comprehensive Apheresis
Solutions for Cell Collections
Service
Description
Variability in donor biology, inconsistencies in cell yield, and stringent regulatory complexities present critical challenges in cell and gene therapy manufacturing, affecting both scalability and clinical efficacy. At CCS, we provide specialized GMP-compliant apheresis procedures that maximize cell viability and deliver high-quality, regulatory-compliant cellular starting materials for cell and gene therapy manufacturing.
Our expansive apheresis network, spanning hospitals, research institutions, and clinical sites, enables seamless donor access and reliable cell sourcing for advanced therapies. With strategically located collection centers and established hospital partnerships, we ensure consistent, high-yield cell procurement to meet the rigorous demands of manufacturing and clinical applications.
Our apheresis services ensure the safe and efficient collection of peripheral blood mononuclear cells (PBMCs), hematopoietic progenitor cells (HPCs), and leukapheresis-derived products used in CAR-T therapies, induced pluripotent stem cell (iPSC) research, and advanced therapies applications.
Effective donor selection is fundamental to ensuring immune compatibility, maintaining consistent cell viability, and manufacturing success. Our donor management services include rigorous donor screening and management, HLA matching, and recallable donor programs, providing biotech and pharma companies with a consistent and high-quality cell supply.
With decades of experience in apheresis services for clinical applications, CCS provides high-quality GMP-compliant apheresis procedures that support both therapeutic treatments and cell collections for cell and gene therapy (CGT). Our team works alongside clinical staff to ensure patient safety, comfort, and regulatory compliance throughout the process.
CCS specializes in therapeutic apheresis, including plasmapheresis, red cell exchange, and erythrocytapheresis, helping to treat hematologic, autoimmune, and neurological disorders. With expertise in leukapheresis-derived products, stem cell mobilization, and cell sourcing, we deliver optimized apheresis collection protocols to support both patient care and advanced therapies.
Unique
Offerings
Advanced
Therapies
We offer flexible apheresis services, including licensed on-site centers and mobile collection staff, designed to meet the evolving needs of cell and gene therapy development. Our high-quality apheresis collection protocols, regulatory expertise, and advanced logistics ensure a reliable supply of viable, well-characterized cells for clinical and research applications. By integrating efficient workflows, compliance-driven procedures, and scalable solutions, we support the seamless advancement of cell and gene therapy manufacturing.
Through our extensive hospital and research partnerships, CCS provides unmatched scalability in donor recruitment and apheresis services, enabling both emerging biotech firms and global pharmaceutical companies to access high-quality cellular starting materials with ease.
High-Precision Apheresis Systems
We utilize automated, closed-system apheresis systems to enhance high-quality cell collection with minimal contamination risk and optimized apheresis collection protocol development.